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As inhibitor of apoptosis (IAP) proteins can regulate additional signaling pathways beyond apoptosis, we investigated the effect
of the second mitochondrial activator of caspases (Smac) mimetic BV6, which antagonizes IAP proteins, on non-apoptotic
functions in glioblastoma (GBM). Here, we identify non-canonical nuclear factor-jB (NF-jB) signaling and a tumor necrosis
factor-a (TNFa)/TNF receptor 1 (TNFR1) autocrine/paracrine loop as critical mediators of BV6-stimulated migration and invasion
of GBM cells. In addition to GBM cell lines, BV6 triggers cell elongation, migration and invasion in primary, patient-derived GBM
cells at non-toxic concentrations, which do not affect cell viability or proliferation, and also increases inﬁltrative tumor growth
in vivo underscoring the relevance of these ﬁndings. Molecular studies reveal that BV6 causes rapid degradation of cellular IAP
proteins, accumulation of NIK, processing of p100 to p52, translocation of p52 into the nucleus, increased NF-jB DNA binding
and enhanced NF-jB transcriptional activity. Electrophoretic mobility shift assay supershift shows that the NF-jB DNA-binding
subunits consistof p50,p52 andRelBfurtherconﬁrming the activation ofthe non-canonical NF-jBpathway.BV6-stimulated NF-
jB activation leads to elevated mRNA levels of TNFa and additional NF-jB target genes involved in migration (i.e., interleukin 8,
monocyte chemoattractant protein 1, CXC chemokine receptor 4) and invasion (i.e., matrix metalloproteinase-9). Importantly,
inhibition of NF-jB by overexpression of dominant-negative IjBa superrepressor prevents the BV6-stimulated cell elongation,
migration and invasion. Similarly, speciﬁc inhibition of non-canonical NF-jB signaling by RNA interference-mediated silencing
of NIK suppresses the BV6-induced cell elongation, migration and invasion as well as upregulation of NF-jB target genes.
Intriguingly, pharmacological or genetic inhibition of the BV6-stimulated TNFa autocrine/paracrine loop by the TNFa-blocking
antibody Enbrel or by knockdown of TNFR1 abrogates BV6-induced cell elongation, migration and invasion. By demonstrating
that the Smac mimetic BV6 at non-toxic concentrations promotes migration and invasion of GBM cells via non-canonical NF-jB
signaling, our ﬁndings have important implications for the use of Smac mimetics as cancer therapeutics.
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Although inhibitor of apoptosis (IAP) proteins were initially
described to function as endogenous caspase inhibitors,
1
X-linked IAP (XIAP) but not cellular IAP1 (cIAP1) and cIAP2
possesses the critical residues for direct inactivation of
caspases.
2 In addition, IAP proteins exert additional functions
besides inhibiting apoptosis, for example, regulation of cell
motility, migration and invasion, although their role in this
context has been controversially discussed. On one side,
XIAP was reported to exert a pro-migratory function in
endothelial cells,
3 to be required for cell motility by regulating
actin polymerization
4 and to cooperate with survivin to foster
cell motility and invasion.
5 Also, cIAP1 was shown to regulate
cell migration in a CARD-dependent manner, as mutation of
its CARD domain increased cell migration.
6 On the other side,
downregulation of XIAP or cIAPs either by siRNA-mediated
knockdown or utilization of second mitochondrial activator of
caspases (Smac) mimetic were recorded to promote cell
migration via phosphorylation of C-RAF and activation of the
MAPK signaling cascade.
7 In addition, depletion of XIAP or
cIAP1 was shown to trigger Rac1 accumulation, thereby
enhancing cell elongation and migration.
8
Furthermore, IAP proteins are key regulators of canonical
and non-canonical nuclear factor-kB (NF-kB) pathways.
1
In resting cells, canonical NF-kB signaling is blocked by
IkBa, which sequesters NF-kB subunits in the cytosol.
9 On
tumor necrosis factor (TNF) receptor 1 (TNFR1) activation,
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www.nature.com/cddisIkBa gets phosphorylated and degraded, leading to p65/p50
nuclear translocation and transcriptional activation of NF-kB
target genes. E3 ligase activity of cIAP proteins promotes
activation of canonical NF-kB signaling by adding K63-linked
ubiquitin chains on RIP1 kinase.
10,11 In the non-canonical
NF-kB pathway, NF-kB-inducing kinase (NIK) is constitutively
degraded via a cIAP/TRAF complex.
12,13 Downregulation of
cIAP proteins leads to NIK accumulation, processing of p100
top52, nuclear translocationofp52 and NF-kB activation.
14,15
NF-kB can control migration and invasion via transcriptional
activation of pro-migratory and pro-invasive genes like CXC
chemokines,urokinase-typeplasminogenactivator(uPA)and
matrix metalloproteinases (MMPs).
16
Glioblastoma (GBM) is the most frequent malignant brain
tumor with a very poor prognosis and its aggressiveness
involves a highly migratory and invasive phenotype.
17,18
Constitutively activated NF-kB has been linked to its invasive
behavior and degree of malignancy.
19,20
Overexpression of IAP proteins correlates with poor prognosis
and treatment resistance of cancers.
4,21,22 Chromosomal ampli-
ﬁcation of 11q22. containing the loci of cIAP1/2 often occurs in
GBM
23 and IAP proteins are overexpressed in GBM cell lines.
24
During apoptosis, IAP proteins are antagonized by Smac that
is released from the mitochondria.
25,26 Similarly, small-molecule
Smac mimetics bind and neutralize IAP proteins.
1 In this study,
we investigated the role of the Smac mimetic BV6 in the
regulation of migration and invasion using GBM as a model.
Results
BV6 at non-toxic concentration stimulates cell elonga-
tion of GBM cells. To investigate whether non-toxic
concentrations of the Smac mimetic BV6 regulates additional
pathways besides apoptosis in GBM cells, we initially
determined its non-lethal concentrations. Concentrations of
BV6 up to a 2.5mM had no effect on cell viability or caspase-3
activation (Figures 1a and b). To control the biological activity
of BV6 at these conditions we assessed IAP protein levels,
because BV6 triggers autoubiquitination of IAP proteins.
14
BV6 caused profound depletion of cIAP1 protein in all three
cell lines consistent with a previous report that cIAP1 is
especially susceptible to Smac mimetic-stimulated degrada-
tion.
14,15,27 In addition, BV6-triggered degradation of XIAP
and cIAP2 in T98G and LN229 cells, whereas U87MG cells
showed no changes in XIAP levels and little expression of
cIAP2 protein (Figure 1b). Therefore, we used 2.5mM BV6
for all subsequent experiments as a non-toxic concentration
that causes depletion of cIAP proteins.
BV6
DMSO BV6
DMSO
0
50
100
150
200
0 1 2.5
T98G
U87MG
LN229
0
1
2
3
BV6
***
-+
caspase-3
cIAP1
XIAP
cIAP2
BV6 - + - + -  +
T98G U87MG LN229
68 kD
68 kD
57 kD
32 kD
42 kD
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
[
%
]
β-actin
BV6 [μM]
E
l
o
n
g
a
t
i
o
n
 
i
n
d
e
x
 
[
f
o
l
d
 
i
n
c
r
e
a
s
e
]
Figure 1 BV6 triggers cell elongation of GBM cells. (a) T98G, U87MG and LN229 GBM cells were treated for 24h with indicated concentrations of BV6 or DMSO. Cell
viability was measured by MTT assay and is expressed as the percentage of untreated controls. (b) T98G, U87MG and LN229 cells were treated for 24h with 2.5mM BV6 or
DMSO.ExpressionlevelsofcIAP1,cIAP2,XIAPandcaspase-3wereanalyzedbywesternblotting.Expressionofb-actinservedasloadingcontrol.(candd)T98Gcellswere
treatedfor 24h with 2.5mM BV6 or DMSO.Cell morphology was analyzedby phase-contrast microscope; scale bar: 250mm( c). Cell elongation was quantiﬁed by measuring
cell length and width and by calculatingcell elongation index (length/width); fold increase in elongation index in the presence and absenceof BV6 is shown (d). (e) T98G cells
weretreatedfor24hwith2.5mMBV6orDMSO.PolymerizationofF-actinwasanalyzedbyphalloidinstaining;scalebar:20mm.In(b,cande),representativeexperimentsof
three independent experiments are shown. In (a and d), meanþS.D. of three independent experiments performed in triplicate are shown; ***Po0.005
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2
Cell Death and DiseaseTo examine the effect of BV6 on non-apoptotic functions,
we monitored the morphology of T98G cells by time-lapse
microscopy. Interestingly, we observed that treatment with
BV6-stimulated cell elongation with long cytoplasmic exten-
sions compared with control cells with round shape and short
cytoplasmic extensions (Figures 1c and d). To analyze actin
polymerization as a typical feature of cell motility, we stained
cells for ﬁlamentous actin (F-actin). Confocal microscopy
showed that BV6-treated T98G cells exhibited long F-actin-
rich protrusions suggesting that BV6 stimulates changes in
the cytoskeleton that are associated with cell motility
(Figure 1e).Thus,BV6 atasublethalconcentration stimulates
cell elongation of GBM cells.
BV6 at non-toxic concentration triggers migration and
invasion of GBM cells and increases inﬁltrative growth
of GBM in vivo. Based on our ﬁndings that BV6 stimulates
morphological changes associated with increased cell
motility, we next investigated whether BV6 has an effect on
migration and invasion of GBM cells. Transwell migration
assays showed that BV6 signiﬁcantly increased migration
of T98G, U87MG and LN229 cells (Figures 2a and b).
In addition, BV6 signiﬁcantly enhanced invasion of GBM cells
(Figure 2c). To control that these BV6-stimulated changes in
migration and invasion were not simply because of altera-
tions in proliferation and/or cell cycle, we monitored these
parameters in parallel. BV6 did not signiﬁcantly change
proliferation (Supplementary Figure S1A) or cell cycle
distribution (Supplementary Figure S1B) at non-toxic condi-
tions. Taken together, these data demonstrate that BV6
triggers migration and invasion of GBM cells.
Next, we asked whether BV6 also stimulates invasiveness
of GBM cells in vivo. To address this question we used the
chicken chorioallantoic membrane (CAM) model, an estab-
lished preclinical tumor model.
28,29 T98G cells were treated
for 24h with BV6 and were then seeded on the CAM of
chicken embryos to allow tumor growth in vivo, which was
assessed after 4 days. Importantly, pre-treatment of GBM
cells with BV6 substantially increased the percentage of
tumors with inﬁltrative growth in vivo compared with tumors
derived from untreated GBM cells (Figure 2d). These data
indicatethatBV6increasestheinﬁltrativegrowthofGBMcells
in vivo.
BV6 at non-toxic concentration activates the NF-jB
pathway. Next, we aimed at identifying the underlying
molecular mechanisms responsible for the BV6-stimulated
cell elongation, migration and invasion. To this end, we
examined the effect of BV6 on NF-kB signaling, because
BV6-mediated downregulation of IAP proteins has been
reported to lead to NF-kB activation.
14 To monitor activation
of the canonical NF-kB pathway, we analyzed IkBa
phosphorylation. IkBa was slightly phosphorylated after 2h
of BV6 stimulation accompanied by a slight decrease in IkBa
protein levels (Figure 3a). As positive control for canonical
NF-kB signaling, we used TNFa, which potently stimulated
phosphorylation and degradation of IkBa protein already
after 5min (Figure 3a). For monitoring non-canonical NF-kB
activation, we assessed accumulation of NIK protein and
proteolytic processing of p100 to p52. BV6 rapidly caused
accumulation of NIK and processing of p100 to p52
(Figure 3b). NIK accumulation and p100 processing to p52
was similarly detected in all three GBM cell lines (Figure 3c).
To analyze that NF-kB subunits translocate into the nucleus,
we prepared cytosolic and nuclear extracts. BV6 stimulated
nuclear translocation of p52 and p50 and slightly that of p65,
whereas TNFa primarily triggered p65 translocation
(Figure 3d). DNA-binding assays showed that BV6 stimu-
lated NF-kB DNA binding within the ﬁrst hours of stimulation
and over a prolonged time up to at least 24h (Figure 3e).
Interestingly, electrophoretic mobility shift assay (EMSA)
supershift assay revealed that NF-kB DNA-binding
complexes on stimulation with BV6 were mainly composed
of p50, p52 and RelB subunits, because the addition of p50,
p52 and/or RelB antibodies to nuclear extracts resulted in a
supershift (for p50 antibody) or immunodepletion (for p52
and/or RelB antibodies) of DNA-binding complexes
(Figure 3f). By comparison, p65 contributed to a minor
extent to BV6-triggered NF-kB complex formation, indicating
that BV6 mainly triggers non-canonical NF-kB signaling.
As prototypic stimulus of the canonical NF-kB pathway,
TNFa-triggered increased DNA-binding of the p65 subunit
and also of p50 (Figure 3f). To determine whether NF-kB
DNA-binding leads to transcriptional activation of NF-kB
target genes we performed luciferase assay. BV6 signiﬁ-
cantly increased NF-kB transcriptional activity (Figure 3g).
These experiments show that BV6 activates NF-kB signaling
and in particular the non-canonical pathway in GBM cells
resulting in enhanced NF-kB transcriptional activity.
NF-jB is required for BV6-induced cell elongation,
migration and invasion. We next asked whether NF-kB
activation is required for BV6-induced changes in cell shape
and motility of GBM cells. To address this question, we
overexpressed IkBa superrepressor (IkBa-SR) in T98G cells
to inhibit NF-kB (Figure 4a). Control experiments showed
that IkBa overexpression potently suppressed BV6- and
TNFa-stimulated NF-kB activation (Figure 4b) without altering
cell viability on treatment with BV6 (Supplementary Figure
S1C). Interestingly, inhibition of NF-kBb yI kBa-SR resulted in
increased NIK levels accompanied by profound downregula-
tion of cIAP2 expression (Figure 4c). As cIAP2 is a prototypic
NF-kB target gene and functions in complex with TRAF2/3
as E3 ligase for NIK,
12,13 reduced cIAP2 expression on
NF-kB inhibition may account for stabilization of NIK protein.
In addition, inhibition of NF-kBb yI kBa-SR resulted in reduced
expression of additional NF-kB target genes, including p100,
RelB and cIAP1 (Figure 4c).
30,31 As a side note, the short
incubation time with BV6 to assess NIK accumulation (3h)
may account for the fact that treatment with BV6 did not yet
result in depletion of cIAP2 protein in this experiment
(Figure 4c) compared with cIAP2 degradation in parental
T98G cells on prolonged incubation with BV6 for 24h
(Figure 1b). Importantly, NF-kB inhibition prevented the BV6-
stimulated cell elongation compared with control cells (Figures
4d and e). Also, the BV6-triggered increase in migration and
invasion was blocked in IkBa-SR-overexpressing cells com-
pared with control cells (Figures 4f and g). Together, this set
of experiments demonstrates that NF-kBi sr e q u i r e df o r
BV6-stimulated cell elongation, migration and invasion.
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Cell Death and DiseaseTNFa/TNFR1 autocrine/paracrine signaling is required
for BV6-induced cell elongation, migration and invasion.
As TNFa is one of the key NF-kB target genes and has
been described to regulate migration and invasion,
16,32
we analyzed whether TNFa is upregulated on BV6 treatment.
Quantitative RT-PCR analysis showed that within 3h BV6
rapidly stimulated an increase in TNFa mRNA levels
(Figure 5a). Besides TNFa, BV6 increased mRNA levels of
additional NF-kB target genes controlling cell migration,
including the chemokines interleukin 8 (IL-8), monocyte
chemoattractant protein 1 (MCP-1) and CXC chemokine
receptor type 4 (CXCR4), or regulating migration such as the
protease MMP9, whereas little or no changes in uPA and
MMP2 mRNA levels were found (Figure 5b).
To test whether TNFa/TNFR1 signaling is required for the
BV6-induced cell elongation, migration and invasion, we used
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Figure 3 BV6 activates the non-canonical NF-kB pathway. (a) T98G cells were treated for indicated times with 2.5mM BV6 or DMSO; stimulation with 10ng/ml TNFa for
5min was used as positive control. Phosphorylation and expression of IkBa were analyzed by western blotting. Expression of a-tubulin served as loading control. (b) T98G
cells were treated for indicated times with 2.5mM BV6 or DMSO. Expression levels of NIK, p100, p52 and cIAP1 were analyzed by western blotting. Expression level of
GAPDHservedasloadingcontrol.(c)T98G,U87MGandLN229cellsweretreatedfor24hwith2.5mMBV6orDMSO.ExpressionlevelsofNIK,p100andp52wereanalyzed
by western blotting. Expression of GAPDH served as loading control. (d) T98G, U87MG and LN229 cells were treated for 24h with 2.5mm BV6 or DMSO; stimulation with
10ng/ml TNFa for 1h was used as positive control. Expression levels of p100, p52, p50, phospho-p65 (p-p65) and p65 were analyzed in cytoplasmic (C) and nuclear (N)
fractions by western blotting. a-tubulin served as loading control for cytoplasmic fractions and lamin A/C for nuclear fractions. (e) T98G cells were treated for indicated times
with 2.5mM BV6 or DMSO; stimulation with 10ng/ml TNFa for 1h was used as positive control. Nuclear extracts were analyzed for NF-kB DNA-binding activity by EMSA. (f)
T98Gcellsweretreatedfor6hwith2.5mMBV6orDMSOorwith10ng/mlTNFafor1h.NuclearextractswereanalyzedforthecompositionofNF-kBDNA-bindingcomplexes
byEMSAsupershiftusingtheindicatedantibodies.(g)T98Gcellsweretreatedfor24hwith2.5mMBV6orDMSO.NF-kBtranscriptionalactivitywasdeterminedbyluciferase
assayandfold increasein luciferase activityis shown.MeanþS.D. of three independent experiments performedin triplicateare shown; ***Po0.005.In (a–f),representative
experiments of three (a–e) or two (f) independent experiments are shown
Figure 2 BV6 triggers migration and invasion of GBM cells. (a and b) T98G, U87MG and LN229 cells were treated with 2.5mM BV6 or DMSO and allowed to migrate for
24h in a transwell migration chamber. Migrated cells were ﬁxed, stained with crystal violet and pictures were taken by phase-contrast microscope (scale bar: 500mm);
a representative experiment of three independent experiments is shown (a). Migration was quantiﬁed by dissolution of crystal violet staining and determination of optical
density; fold increase in migration is shown (b). (c) T98G, U87MG and LN229 cells were cultivated for 24h in FITC-collagen containing 2.5mM BV6 or DMSO. Invasion was
assessed by determining the amount of FITC released into the supernatant. Fold increase in invasion in the presence and absence of BV6 is shown. (d) T98G cells were
treatedfor 24h with 2.5mM BV6 or DMSO for in vivo invasionassay. After treatment, one millioncells were seededon the CAM of chicken embryos and allowedto growfor 4
days. Tumor formation (tumor40.5cm
3) and inﬁltrative growth (growth of tumor cells inside the CAM) were analyzed by hematoxylin eosin-stained parafﬁn sections of the
CAM.Representativepicturesfromthreeindependentexperimentsareshown(n¼30eggs).Lowermagniﬁcation(upperpictures):  3;highermagniﬁcation(lowerpictures):
 4; scale bar: 500mm. The number and percentage of tumor formation and inﬁltrative tumors are indicated. In (b and c), meanþS.D. of three independent experiments
performed in duplicate are shown; *Po0.05
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Cell Death and Diseasethe soluble TNFa antibody Enbrel as a pharmacological
approach to abolish a putative TNFa autocrine/paracrine
signaling loop. Control experiments showed that Enbrel
neither alone nor in combination with BV6 was cytotoxic to
T98G cells (Supplementary Figure S2A), whereas it potently
blocked DNA fragmentation after co-treatment with BV6 and
TNFa that was used as a positive control for Enbrel
(Supplementary Figure S2B). Interestingly, the addition of
Enbrel inhibited the BV6-stimulated increase in cell elonga-
tion, migration and invasion, whereas Enbrel alone had no
effect on these parameters (Figures 5c–e). In a second
genetic approach to block TNFa/TNFR1 signaling, we
knocked down TNFR1 by RNA interference (Figure 6a).
Control experiments showed that TNFR1 knockdown did not
affect sensitivity towards BV6, whereas it signiﬁcantly
reduced DNA fragmentation after co-treatment with BV6 and
TNFa that was used as a positive control for TNFR1
knockdown (Supplementary Figures S2C, S2D). Importantly,
TNFR1 knockdown prevented the BV6-induced cell elonga-
tion, migration and invasion, whereas BV6 signiﬁcantly
increased cell elongation, migration and invasion in non-
silencing control cells (Figures 6b–d). To investigate whether
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Figure 4 NF-kB is required for BV6-induced cell elongation, migration and invasion. (a) T98G cells were transduced with IkBa-SR or vector control and analyzed for
expression of IkBa by western blotting. a-tubulin expression served as a loading control. (b) T98G cells stably expressing IkBa-SR or vector control were treated for 3h with
2.5mMBV6orDMSO,stimulationwith10ng/mlTNFafor1hwasusedaspositivecontrol.NuclearextractswereanalyzedbyEMSAforNF-kBDNA-bindingactivity.(c)T98G
cellsstablyexpressingIkBa-SRorvectorcontrolweretreatedfor24hwith2.5mMBV6orDMSO.ExpressionlevelsofNIK,p100,p52,RelB,cIAP1andcIAP2wereanalyzed
by western blotting. Expression of GAPDH served as loading control. (d and e) T98G cells stably expressing IkBa-SR or vector control were treated for 24h with 2.5mM BV6
orDMSO.Cellmorphologywasanalyzedbyphase-contrastmicroscope;scalebar:50mm.Arepresentativeexperimentofthreeexperimentsisshown(d).Cellelongationwas
quantiﬁed by measuring cell length and width and by calculating cell elongation index (length/width); fold increase in elongation index is shown (e). (f) T98G cells transduced
withIkBa-SRor vectorcontrolweretreatedwith 2.5mM BV6orDMSO andallowed tomigratefor 24hina transwellmigration chamber.Migratedcellswereﬁxedandstained
with crystal violet. Migration was quantiﬁed by dissolution of crystal violet staining and determination of optical density. (g) T98G cells transduced with IkBa-SR or vector
control were treated with 2.5mM BV6 or DMSO and allowed to invade for 24h in a collagen-coated transwell migration chamber. Invasive cells were ﬁxed and stained with
crystalviolet.Invasionwasquantiﬁedbydissolutionofthecrystalvioletstaininganddeterminationofopticaldensity.In(a–d),arepresentativeexperimentoftwo(a–c)orthree
(d) independent experiments is shown. In (e–g), meanþS.D. of three independent experiments are shown; *Po0.05; **Po0.01; n.s. not signiﬁcant
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Cell Death and Diseaseincreased mRNA levels of IL-8, MCP-1 and MMP9 are also
a consequence of TNFa autocrine/paracrine signaling, we
determined mRNA levels of these cytokine genes in the
presence and absence of Enbrel. The addition of Enbrel
reduces the BV6-triggered upregulation of IL-8, MCP-1 and
MMP9 mRNA levels (Supplementary Figure S2E) indicating
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Figure 5 TNFa is required for BV6-induced cell elongation, migration and invasion. (a) T98G cells were treated for indicated times with 2.5mM BV6 or DMSO. TNFa
mRNA levels were analyzed by quantitative RT-PCR and fold increase in TNFa mRNA levels is shown. MeanþS.D. values of two independent experiments are shown.
(b) T98G cells were treatedwith 2.5mM BV6 or DMSO. mRNAlevels of indicatedNF-kB target genes were analyzedby quantitative RT-PCRand are shown as fold increase
for maximal induction (IL-8 and MCP-1 after 6h, CXCR4 after 9h, uPA and MMP9 after 24h). MeanþS.D. values of two independent experiments are shown. (c–e) T98G
cells were treated for 24h with 2.5mM BV6 and/or 100mg/ml Enbrel. Cell morphology was analyzed by phase-contrast microscope. Cell elongation was quantiﬁed by
measuringcelllengthandwidthandbycalculatingcellelongationindex(length/width);foldincreaseinelongationindexisshown(c).Migratedcellswereﬁxedandstainedwith
crystal violet. Migration was quantiﬁed by dissolution of crystal violet staining and determination of optical density (d). Cells were allowed to invade in a collagen-coated
transwell migration chamber; invasive cells were ﬁxed, stained with crystal violet and optical density was measured (e). In (c–e) meanþS.D. values of three independent
experiments performed in triplicate (c) and duplicate (d and e) are shown; *Po 0.05; **Po0.01; n.s. not signiﬁcant
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Figure6 TNFR1knockdowninhibitsBV6-inducedcellelongation,migrationandinvasion.(a)T98GcellswerelentivirallytransducedwithshRNAagainstTNFR1orvector
control and knockdown of TNFR1 was assessed by western blotting. GAPDH expression served as loading control. (b–d) T98G cells transduced with shRNA against TNFR1
orcontrolvectorweretreatedfor 24hwith 2.5mM BV6. Cellmorphologywas analyzedbyphase-contrastmicroscope. Cellelongationwas quantiﬁedbymeasuringcelllength
and width and by calculating cell elongation index (length/width); fold increase in elongation index is shown (b). Migrated cells were ﬁxed and stained with crystal violet.
Migration was quantiﬁed by dissolution of crystal violet staining and determination of optical density (c). Cells were allowed to invade in a collagen-coated transwell migration
chamber; invasive cells were ﬁxed, stained with crystal violet and optical density was measured (d). In (a), a representative experiment of two independent experiments is
shown, in (b–d) meanþS.D. values of three independent experiments performed in triplicate (b) or duplicate (c and d) are shown; *Po0.05; n.s. not signiﬁcant
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Cell Death and Diseasethat TNFa autocrine/paracrine signaling is involved in BV6-
induced increase in IL-8, MCP-1 and MMP9 expression.
Together, this set of experiments demonstrates that BV6
increases the expression of NF-kB target genes including
TNFa, which in turn engages a TNFa/TNFR1 autocrine/
paracrine signaling loop that is required for the BV6-induced
cell elongation, migration, invasion and induction of NF-kB
target genes.
NIK is required for BV6-induced cell elongation,
migration and invasion. To further investigate the role
of the non-canonical NF-kB pathway, we created T98G cells
with knockdown of NIK (shNIK; Supplementary Figure S3A).
Control experiments showed that NIK knockdown reduced
BV6-stimulated NIK accumulation, p100 processing to
p52 and NF-kB DNA-binding compared with non-silencing
control cells (Figures 7a and b). By comparison,
NIK silencing did not interfere with NF-kB binding on TNFa
stimulation (Figure 7b), consistent with activation of the
canonical NF-kB pathway by TNFa (Figures 3a and f).
Control experiments also showed that NIK knockdown
did not alter the sensitivity toward BV6 compared with
control cells (Supplementary Figure S3B). Importantly, NIK
silencing prevented BV6-stimulated increase in cell
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Figure7 NIKisrequiredforBV6-inducedcellelongation,migrationandinvasion.(a)T98GcellstransducedwithshRNAagainstNIKorvectorcontrolweretreatedfor24h
with 2.5mM BV6. Expression levels of NIK, p100, p52 and cIAP1 were analyzed by western blotting. Expression of GAPDH served as loading control. (b) T98G cells
transducedwithshRNAagainstNIK(shNIK)orvectorcontrolweretreatedfor2and24hwith2.5mMBV6,stimulationwith10ng/mlTNFafor1hwasusedaspositivecontrol.
Nuclear extracts were prepared and analyzedfor NF-kB DNA-binding activity by EMSA. NIK knockdown slightly reduced BV6-stimulated NF-kB DNA-binding after treatment
with BV6for24h comparedwithnon-silencingcontrolcells.(c–e)T98Gcellstransducedwith shRNAagainstNIKor vectorcontrolweretreatedfor24h with 2.5mM BV6.Cell
morphology was analyzed by phase-contrast microscope. Cell elongation was quantiﬁed by measuring cell length and width and by calculating cell elongation index (length/
width); fold increase in elongation index is shown (c). Migrated cells were ﬁxed and stained with crystal violet. Migration was quantiﬁed by dissolution of crystal violet staining
anddeterminationofopticaldensity(d).Cellswereallowedtoinvadeinacollagen-coatedtranswellmigrationchamber;invasivecellswereﬁxed,stainedwithcrystalvioletand
optical density was measured (e). (f) T98G cells transduced with shRNA against NIK or vector control were treated for indicated times with 2.5mM BV6. TNFa mRNA levels
were analyzed by quantitative RT-PCR and fold increase in TNFa mRNA levels is shown. (g) T98G cells transduced with shRNA against NIK or vector were treated with
2.5mMBV6.mRNAlevelsofindicatedNF-kBtargetgeneswereanalyzedbyquantitativeRT-PCRandareshownasfoldincreaseformaximalinduction(IL-8andMCP-1after
6h, and MMP9 after 24h). In (a and b), representative experiments from two (a) or three (b) experiments are shown. In (c–g), meanþS.D. values of three (c–e) or two
(f and g) independent experiments performed in triplicate (c, f and g) and duplicate (d and e) are shown; *Po0.05; **Po0.01; n.s. not signiﬁcant
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Cell Death and Diseaseelongation, migration and invasion compared with control
cells (Figures 7c–e).
As our results show that TNFa is upregulated on BV6
treatment (Figure 6a) and required for BV6-stimulated cell
elongation, migration and invasion (Figures 6b–d), we next
analyzed whether TNFa levels increase in a NIK-dependent
manner. Interestingly, BV6-stimulated upregulation of TNFa
was strongly reduced in NIK knockdown cells compared with
non-silencing control cells (Figure 7f). In addition, the BV6-
mediated upregulation of IL-8, MCP-1 and MMP9 was
profoundly suppressed in NIK knockdown cells (Figure 7g).
These experiments indicate that NIK is required for BV6-
induced cell elongation, migration, invasion and induction of
NF-kB target genes.
BV6 triggers cell elongation, migration and invasion in
primary GBM cells. To test the potential clinical relevance
of our ﬁndings, we extended our experiments to primary
GBM cells derived from patients’ specimens. BV6 at low
micromolar concentrations caused profound depletion of
cIAP1 without altering cell viability or triggering caspase-3
cleavage, whereas BV6 had no or minor effects on
expression levels of cIAP2 and XIAP (Figures 8a and b).
Also, BV6 induced accumulation of NIK protein and p100
processing to p52, indicating that it stimulates non-canonical
NF-kB signaling in primary GBM cells (Figure 8c). Impor-
tantly, BV6 signiﬁcantly increased cell elongation, migration
and invasion of both GBM1 and GBM2 cells (Figures 8d–f).
These ﬁndings demonstrate that BV6 at non-toxic
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Figure 8 BV6 triggers cell elongation, migration and invasion of primary GBM cells. (a) Primary GBM cells derived from two distinct specimens (GBM1, GBM2) were
treated for 24h with indicated concentrations of BV6. Cell viability was measured by MTT assay and is expressed as the percentage of untreated controls. (b) Primary GBM
cells were treated with BV6 (GBM1: 1mM BV6, GBM2: 0.8mM BV6) for 24h. Expression levels of cIAP1, cIAP2, XIAP and caspase-3 were analyzed by western blotting.
Expression level of GAPDH served as loading control. (c) Primary GBM cells were treated with BV6 (GBM1: 1mM BV6, GBM2: 0.8mM BV6) for 24h. Expression levels of
p100,p52andcIAP1wereanalyzedbywesternblotting.ExpressionlevelofGAPDHservedasaloadingcontrol.(d–f)PrimaryGBMcellsweretreatedwithBV6(GBM1:1mM
BV6, GBM2: 0.8mM BV6) for 24h. Cell morphology was analyzed by phase-contrast microscope. Cell elongation was quantiﬁed by measuring cell length and width and by
calculatingcellelongationindex(length/width);foldincreaseinelongationindexisshown(d).Migratedcellswereﬁxedandstainedwithcrystalviolet.Migrationwasquantiﬁed
by dissolution of crystal violet staining and determination of optical density (e). Cells were allowed to invade in a collagen-coated transwell migration chamber; invasive cells
were ﬁxed, stained with crystal violet and optical density was measured (f). In (a, d–f), meanþS.D. values of three independent experiments performed in triplicate (a and d)
and in duplicate (e and f) are shown; *Po0.05. In (b and c), representative experiments from two experiments are shown
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Cell Death and Diseaseconcentrations activates the non-canonical NF-kB pathway
and triggers cell elongation, migration and invasion in primary
GBM cells.
Discussion
We previously reported that small-molecule IAP antagonists
such as Smac mimetic act in concert with cytotoxic strategies
including chemotherapeutics, TRAIL or irradiations to
induce apoptosis in GBM cells.
33–36 Here, we report that the
Smac mimetic BV6 as single agent at non-toxic concentra-
tions exerts non-apoptotic functions in GBM cells: BV6
promotes cell elongation, migration and invasion of GBM
cells by activating non-canonical NF-kB signaling and a
TNFa/TNFR1 autocrine/paracrine loop. This conclusion is
supported by several independent pieces of evidence.
First, treatment of GBM cells with BV6 results in predominant
activation of the non-canonical NF-kB pathway as demon-
strated by accumulation of NIK protein, proteolytic processing
of p100 to p52, translocation of p52 from the cytosol into the
nucleus, binding of the NF-kB subunits p52, p50 and
RelB to the DNA, transcriptional activation of NF-kB and
increased mRNA expression of NF-kB target genes including
TNFa. By comparison, non-toxic concentrations of BV6
only slightly stimulate the canonical NF-kB pathway in GBM
cells. Second, overexpression of IkBa-SR blocks activation
of the non-canonical NF-kB pathway and suppresses
BV6-stimulated cell elongation, migration and invasion.
Decreased expression levels of key components of the
non-canonical NF-kB pathway such as p100 and RelB,
which are NF-kB target genes,
30,31 may contribute to
inhibition of non-canonical NF-kB signaling in IkBa-SR-over-
expressingcells. Third, speciﬁcinhibitionofthe non-canonical
NF-kB pathway by RNAi-mediated knockdown of NIK
inhibits the BV6-induced cell elongation, migration and
invasion as well as upregulation of NF-kB target genes
such as TNFa. Fourth, inhibition of the TNFa/TNFR1
autocrine/paracrine loop either by a pharmacological
approach using the TNFa-blocking antibody Enbrel or by a
genetic strategy via RNAi-mediated silencing of TNFR1
suppresses cell elongation, migration and invasion on
exposure to BV6. Together, these data underscore the critical
role of non-canonical NF-kB signaling for BV6-stimulated cell
elongation, migration and invasion.
The novelty of our study resides in the identiﬁcation of the
non-canonical NF-kB pathway as a critical mediator of BV6-
triggered cell elongation, migration and invasion of GBMcells.
By monitoring activation of both the non-canonical and the
canonical NF-kB pathway at different levels of the signaling
cascade, we demonstrate that non-toxic concentrations of
BV6 predominately stimulate non-canonical NF-kB signaling.
This identiﬁcation of non-canonical NF-kB signaling as a key
mediatorofthenon-apoptoticfunctionsofBV6inthecontrolof
migration and invasion is particularly interesting in compar-
ison with previous studies reporting that non-canonical NF-kB
signaling is required for Smac mimetic-triggered cytotoxicity.
This indicates that the non-canonical NF-kB pathway is
involved in the regulation of both non-apoptotic and apoptotic
processes on treatment with Smac mimetic in a context-
dependent manner. Of note, in this study we used non-toxic
concentrations of BV6 that cause depletion of cIAP proteins
and activation of the non-canonical NF-kB pathway but do not
affect cell viability or proliferation. Thus, Smac mimetic may
differentially engage non-apoptotic and apoptotic pathways in
a concentration-dependent manner. The slight activation of
the canonical NF-kB pathway in our model may occur via a
crosstalk with the non-canonical NF-kB pathway, because
NIK has been described to also interact and phosphorylate
IKKb, although IKKa is known as a preferential substrate for
NIK.
37,38 Althoughthe impact ofthe canonicalNF-kB pathway
on migration and invasion has been extensively studied,
16
there are only a few reports on the role of non-canonical
NF-kB signaling in this context. In a murine system, IKKa
 / 
or p52
 /  macrophages or mouse embryo ﬁbroblasts were
demonstrated to fail to migrate toward the chemoattractant
HMGB1, as they were unable to maintain the production of
CXCL12/SDF1.
39,40 Further, NIK was reported to be neces-
sary for osteopontin-stimulated secretion of uPA, uPA-
dependent activation of pro-MMP-9 as well as cell migration
and invasion.
41
Another important ﬁnding of our study consists in the
identiﬁcation of a TNFa/TNFR1 autocrine/paracrine, non-
apoptotic loop as critical mediator of BV6-stimulated
migration and invasion, because all these effects are
suppressed by the TNFa-blocking antibody Enbrel and in
TNFR1 knockdown cells. Of note, TNFa/TNFR1 autocrine/
paracrine signaling has been implicated to mediate apoptosis
of Smac mimetic at lethal concentrations.
14,15 Thus, Smac
mimetic may differentially engage non-apoptotic and apopto-
tic TNFa/TNFR1-mediated events in a context-dependent
manner. TNFa/TNFR1-stimulated signaling may contribute to
non-canonical NF-kB activation during BV6-stimulated
migration and invasion. In RIP1-deﬁcient cells, TNFR1
crosslinking was shown to engage the non-canonical NF-kB
pathway via TRAF2 downregulation.
42,43 However, we found
no evidence that TRAF2 expression decreases on BV6
stimulation (data not shown). Thus, further studies are
required to explore whether TNFa/TNFR1 signaling is linked
to non-canonical NF-kB pathway in our model.
The role of IAP proteins in cell migration has been
controversially discussed, as some studies reported that
IAP proteins promote motility and migration,
3,5,6 whereas
others – similar to our ﬁndings – demonstrated that migration
is enhanced on depletion of IAP proteins.
7,8 How can these
controversies bereconciled? Itis interesting tonote that these
studies differwith respect to whether or not NF-kB isactivated
and which NF-kB pathway is predominantly engaged on
depletion of IAP proteins. Although we found that BV6
primarily stimulates the non-canonical NF-kB pathway,
Mehrotra et al.
5 reported that XIAP and survivin act together
to activate canonical NF-kB signaling, whereas in another
study Smac mimetic was shown to exert no effect on NF-kB
transcriptional activity.
6 The differences may also be
explained by the balance in proliferation and cell death
controlled by IAP proteins. As IAP proteins are key repressors
of apoptosis, a decrease in their expression levels might
promote cell death. This underscores the relevance of taking
into consideration whether or not depletion of IAP proteins
affects the rate of proliferation and/or cell death, as such
effects may also have an impact on migration and invasion.
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Cell Death and DiseaseAlthough we showed that non-toxic concentrations of BV6 do
not alter proliferation, cell cycle progression or cell death, loss
of cIAP1/2 was previously reported to reduce the proliferation
rate.
6 Furthermore, the approach to antagonize IAP proteins
in cancer cells, that is, via genetic manipulation of by
pharmacological means, may affect the functional outcome.
Also, the cellular context including differences in cell types
(e.g., cancer versus non-malignant cells, mammalian versus
murine models) may have an inﬂuence on the phenotype
that is observed on depletion of IAP proteins. Moreover, the
relative expression levels of distinct IAP proteins within
the cells and the spectrum of IAP proteins that are neutralized
by various Smac mimetics could encounter for differences in
cellular responses.
Pharmacological antagonists of IAP proteins such as Smac
mimetics are currently under evaluation in early clinical trials,
thus highlighting the signiﬁcance of studies to elucidate the
impact of Smac mimetic on non-apoptotic as well as apoptotic
functions. The potential clinical relevance of our ﬁndings is
underlined by parallel experiments in primary GBM cells
derivedfrompatient-derivedtumorspecimens,whichsimilarly
demonstrate that BV6 at a non-lethal concentration activates
non-canonical NF-kB signaling and promotes cell elongation,
migration and invasion. In addition, the BV6-stimulated
increase in the invasiveness of GBM cells is reproduced in
an in vivo model.
In summary, we identify non-canonical NF-kB signaling as
an important mediator of BV6-stimulated migration and
invasion of GBM cells. These ﬁndings have important
implications for the application of Smac mimetics as cancer
therapeutics.
Materials and Methods
Cell culture and chemicals. Human GBM cell lines T98G, U87MG and
LN229 were obtained from ATCC (Manassas, VA, USA) and grown in DMEM
medium (Invitrogen, Karlsruhe, Germany) supplemented with 1% penicillin/streptomycin,
1% sodium pyruvate (both from Invitrogen) and 10% fetal calf serum (Invitrogen). The
bivalent Smac mimetic BV6 (ref. 14) was kindly provided by Genentech (South San
Francisco, CA, USA), recombinant human TNFa was purchased from Biochrom (Berlin,
Germany), MG132 from Enzo Life Sciences (Lo ¨rrach, Germany). Enbrel was kindly
provided by Pﬁzer (Berlin, Germany). All chemicals were obtained from Sigma
(Deisenhofen, Germany) unless indicated otherwise.
Transduction. Overexpression of the dominant-negative IkBa-SR was
performed by retroviral transduction using IkBa (S32; 36A) and the pCFG5-
IEGZ retroviral vector system as previously described.
44 Knockdown of NIK and
TNFR1 was performed by lentiviral shRNA vectors as previously described.
45
Shortly, HEK293T cells were transfected with 7.5mg pGIPZ-shRNAmir vector,
using calcium phosphate transfection. All pGIPZ-shRNAmir-vectors were
purchased from Thermo Fisher Scientiﬁc (Dreieich, Germany) (non-silencing
control (NS): RHS4346, shNIK shRNA: RHS4430-99889385, shTNFR1 shRNA:
RHS4430-101168495). Virus-containing supernatant was collected, ﬁltered and
used for spin transduction at 301C in the presence of 8mg/ml polybrene.
Transduced cells were selected with 1mg/ml puromycin (Sigma).
Determination of cell viability. Cell viability was assessed by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to
the manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany).
Determination of cell elongation. Cells were seeded in 12-well plates
1 day before stimulation. Directly after stimulation with BV6, live cell imaging was
performed at 371C under 5% CO2 for 24h using Leica DMI6000B microscope
(Leica Microsystems, Wetzlar, Germany). Images were taken each 15min and
processed using Leica application suite. Three independent experiments were
recorded. Three pictures of each condition of the 24 h time point were selected
and cell length and width of 20 cells per picture were measured using ImageJ
(National Institutes of Health (NIH), Bethesda, MD, USA). Cell elongation index
was calculated by dividing the length by the width.
Determination of migration and invasion. In all, 1 10
5 cells were
seeded onto 8mm transwell migration chambers (Corning Inc., Wiesbaden,
Germany), stimulated by adding 2.5mM BV6 both to the lower and the upper
chambers to avoid any gradient effect and left to migrate for 24h. Cells on the
upper part of the membrane were scraped using a cotton swab. Migrated cells
were ﬁxed in 4% paraformaldehyde and stained with 0.4% crystal violet.
For quantiﬁcation, crystal violet staining was re-solubilized in a solution containing
1% SDS and absorbance was measured at 550nm using a microplate reader
(TECAN Inﬁnite M200, Crailsheim, Germany).
For determination of invasion, cells were mixed with 1.7mg/ml ﬂuorescein
(FITC)-conjugatedcollagentypeI(Invitrogen)solutionandseededina48-wellplate
at the density of 1 10
6cells/ml. After polymerization of collagen, phenolred-free
DMEM medium was added with 2.5mM BV6 or dimethylsulfoxyde (DMSO) for 24h.
As invasive cells degrade the extracellular matrix thereby releasing FITC-
conjugated collagen into the supernatant, invasion was assessed by measuring
absorbanceofthesupernatant at520nmusingamicroplatereader(TECANInﬁnite
M200). Invasion of cells expressing IkBa-SR and NIK or TNFR1 knockdown cells
was analyzedusingtranswell migrationchamberspre-coatedwith collagen(1.4mg/
ml collagen type I) using the same protocol as described above for the transwell
migration assay.
Immunoﬂuorescent staining and confocal microscopy. T98G
cells were grown in labtek chamber slides (BD Biosciences, Heidelberg,
Germany), ﬁxed with 4% paraformaldehyde after treatment with BV6,
permeabilized with 0.1% Triton-100X for 10min and stained overnight at 41C
for F-actin with Oregon green 488 phalloidin (Invitrogen). All images were obtained
using a Nikon C1si confocal microscope (Nikon, Tokyo, Japan). Images were
computer processed in ImageJ and Adobe Photoshop CS3 (Adobe Systems Inc.,
San Jose, CA, USA).
Western blotting. Western blot analysis was performed as described
previously
46 using the following antibodies: anti-cIAP1 (R&D Systems, Inc.,
Wiesbaden-Nordenstadt, Germany), anti-cIAP2 (Epitomics, Burlingam, CA, USA),
anti-XIAP and anti-Smac from BD Biosciences, anti-caspase-3, anti-NIK and anti-
phospho-p65 from Cell Signaling (Beverly, MA, USA), anti-b-actin (Sigma), anti-a-
tubulin (Calbiochem, Darmstadt, Germany), anti-p50, anti-p65, anti-RelB and anti-
TNFR1 from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-p52
(Millipore, Schwalbach, Germany), anti-lamin A/C (Novacastra, Berlin, Germany)
and anti-GAPDH (BioTrend, Cologne, Germany). Donkey anti-mouse IgG, donkey
anti-rabbit IgG or donkey anti-goat IgG labeled with IRDye infrared dyes were
used for ﬂuorescence detection at 700nm 800nm (LI-COR Biotechnology,
Bad Homburg, Germany). Caspase-3 was immunodetected by enhanced
chemoluminescence (Amersham Biosciences, Freiburg, Germany) using an
anti-rabbit IgG-HRP as secondary antibody.
Nuclear extractions and EMSA. Nuclear extracts were prepared as
previously described.
47 Shortly, cells were washed, scraped, and collected by
centrifugation at 2500r.p.m for 5min at 41C. Cells were resuspended in low salt
buffer, lysed for 15min on ice, followed by addition of a 10% Igepal CA-630
solution and centrifugation. The pelleted nuclei were resuspended in high salt
buffer and nuclear supernatants were obtained by centrifugation. DNA-binding
activity of NF-kB was analyzed by EMSA and the following sequence was used as
speciﬁc oligomer for NF-kB: 50-AGTTGAGGGGACTTTCCCAGGC-30 (sense).
Single-stranded oligonucleotides were labeled with g-[32P]-ATP by T4-poly-
nucleotide kinase (MBI Fermentas 17 GmbH, St. Leon-Rot, Germany), annealed
to the complementary oligomer strand and puriﬁed on sephadex columns
(Illustra Nick Columns, GE Healthcare, Piscataway, NJ, USA). Binding reactions
containing 5mg nuclear extract, 1mg Poly(dI:dC) (Sigma), labeled oligonucleotide
(10000c.p.m.) and 5  binding buffer were incubated for 30min on ice. Binding
complexes were resolved by electrophoresis in non-denaturing 6% polyacrylamide
gels using 0.5  TBE as running buffer and assessed by autoradiography.
For EMSA supershift experiments, binding reactions containing 2.5mg nuclear
extract were incubated for 30min at room temperature with 4mg of the
following antibodies before addition of labeled oligonucleotides: anti-p50
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Cell Death and Disease(sc-1190x), anti-p65 (sc-372X), anti-RelB (sc-226X), anti-c-Rel (sc-70X) (all from
Santa Cruz) or anti-p52 (Millipore).
Luciferase assay. The Dual-Luciferase Reporter Assay System (Promega,
Mannheim, Germany) was used to determine ﬁreﬂy and Renilla luciferase activities
according to the manufacturer’s instructions. Cells were seeded in 12-well plates
and transfected both with 3 kB-ﬁreﬂy luciferase vector containing 3 kB
consensus motif (50-CCCTGAAAGG-30) and Renilla luciferase vector under the
control of the ubiquitin promoter using Fugene 6 Transfection Reagent (Roche
Diagnostics). The day after transfection, cells were stimulated with 2.5mM BV6 or
DMSO. After 24h of stimulation, cells were lysed and luciferase activities were
measured with a microplate reader (TECAN Inﬁnite M200). Fireﬂy luciferase
values were normalized to Renilla luciferase values.
Quantitative RT-PCR. Total RNA was extracted using peqGOLD Total RNA
kit from Peqlab Biotechnologie GmbH (Erlangen, Germany) according to the
manufacturer’s instructions. In all, 2mg of total RNA were used to synthetize the
corresponding cDNA using RevertAid H Minus First Strand cDNA Synthesis Kit
(MBI Fermentas GmbH). To quantify gene expression levels, SYBR-Green based
qRT-PCR was performed using the 7900HT fast real-time PCR system from
Applied Biosystems (Darmstadt, Germany). Data were normalized on 18S-rRNA
expression as reference gene. Primers are listed in Supplementary Table 1.
Melting curves were plotted to verify the speciﬁcity of the ampliﬁed products. All
determinations were performed in triplicate. The relative expression of the target
gene transcript and reference gene transcript was calculated as DDCt. Two
independent experiments were done for each gene.
CAM assay and primary GBM cultures. CAM assay was done as
described previously.
28 Brieﬂy, 1 10
6 T98G cells were resuspended in 10ml
serum-free medium and 10ml Matrigel matrix (BD Biosciences) after treatment
with or without 2.5mM BV6 for 24h and implanted on the CAM of fertilized chicken
eggs on day 8 of incubation. Four days after inoculation, tumors were excised with
the surrounding CAM, ﬁxed in 4% paraformaldehyde, embedded in parafﬁn, cut in
5mm sections and stained with 1:1 hematoxylin and 0.5% eosin solution for
histological analysis. Images were digitally recorded with an SZ61 microscope
(Olympus, Center Valley, PA, USA) and tumor area was analyzed using ImageJ
digital imaging software (NIH). Primary GBM cultures (GBM1, GBM2) were
established from surgical specimens obtained from two patients with grade 4
glioma and were characterized and cultured as described previously.
48 The study
was approved by the ethics committee, Medical Faculty, University of Frankfurt.
Statistical Analysis. Statistical signiﬁcance was assessed by two-sided
Student’s t-test using Microsoft Excel (Microsoft Deutschland GmbH, Unter-
schleiheim, Germany).
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